<?xml version="1.0" encoding="utf-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
>

<channel rdf:about="http://www.bioscirep.org">
<title>Bioscience Reports Immediate Publications</title>
<link>http://www.bioscirep.org</link>
<description>Bioscience Reports RSS feed -- Immediate Publications</description>
<prism:issn>0144-8463</prism:issn>
<prism:eIssn>1573-4935 </prism:eIssn>
<prism:publicationName>Bioscience Reports</prism:publicationName>
<items>
 <rdf:Seq>
	<rdf:li rdf:resource="http://www.bioscirep.org/bsr/imps/refer.htm?MSID=BSR20110045" />
	<rdf:li rdf:resource="http://www.bioscirep.org/bsr/imps/refer.htm?MSID=BSR20110033" />
	
 </rdf:Seq>
</items>
<image rdf:resource="http://www.bioscirep.org/images/BSR_PDF_Icon.jpg" />
</channel>

<image rdf:about="http://www.bioscirep.org/images/BSR_PDF_Icon.jpg">
<title>Bioscience Reports</title>
<url>http://www.bioscirep.org/images/BSR_PDF_Icon.jpg</url>
<link>http://www.bioscirep.org</link>
</image>

<item rdf:about="http://www.bioscirep.org/bsr/imps/refer.htm?MSID=BSR20110045">
	<title><![CDATA[Promoter cloning and characterization of the human programmed cell death protein 4 (pdcd4) gene: evidence for ZBP-89 and Sp-binding motifs as essential Pdcd4-regulators]]></title>
	<link>http://www.bioscirep.org/bsr/imps/refer.htm?MSID=BSR20110045</link>
	<description><![CDATA[Pdcd4 is an important novel tumor suppressor inhibiting transformation, translation, invasion and intravasation, and its expression is downregulated in several cancers. However, little is known about the transcriptional regulation and the promoter of this important tumor suppressor. So far the following is the first comprehensive study to describe the regulation of Pdcd4 transcription by ZBP-89, besides characterizing the gene promoter. We identified the transcriptional start sites of the human <i>pdcd4</i> promoter, a functional CCAAT-box, and the basal promoter region. Within this basal region, computer-based analysis revealed several potential binding sites for zinc finger binding proteins, especially for Sp-family members and ZBP-89. We identified four Sp1/Sp3/Sp4 binding elements to be indispensable for basal promoter activity. However, overexpression of Sp1 and Sp3 was not sufficient to enhance Pdcd4 protein expression. Analysis in different solid cancer cell lines showed a significant correlation between <i>pdcd4</i> and <i>zbp-89</i> mRNA amounts. In contrast to Sp transcription factors, overexpression of ZBP-89 led to an enhanced expression of Pdcd4 mRNA and protein. Additionally, specific knockdown of ZBP-89 resulted in a decreased <i>pcdcd4</i> gene expression. Reporter gene analysis showed a significant upregulation of basal promoter activity by cotransfection with ZBP-89, which could be abolished by mithramycin treatment. Predicted binding of ZBP-89 to the basal promoter was confirmed by EMSA data, supershift analysis for ZBP-89. Taken together, data for the first time implicate ZBP-89 as a regulator of Pdcd4 by binding to the basal promoter either alone or by interacting with Sp-family members.]]></description>
	<dc:creator>J Hendrik Leupold, I Ahmed Asangani, G Mudduluru, H Allgayer</dc:creator>
	<dc:date>2011-11-23T15:31:44Z</dc:date>
	<dc:identifier>doi:10.1042/BSR20110045</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-11-23</prism:publicationDate>
</item>

<item rdf:about="http://www.bioscirep.org/bsr/imps/refer.htm?MSID=BSR20110033">
	<title><![CDATA[HIV-TAT-fused FHIT protein functions as a potential pro-apoptotic molecule in hepatocellular carcinoma cells]]></title>
	<link>http://www.bioscirep.org/bsr/imps/refer.htm?MSID=BSR20110033</link>
	<description><![CDATA[Accumulating evidence has demonstrated that fragile histidine triad (FHIT) is a bona fide tumor suppressor gene in a large fraction of human tumors, including hepatocellular cancer. Virus-based delivery system has been developed to transfer FHIT gene into many types of cancer cells to inhibit growth or even induce apoptosis. However, protein-based replacement strategy of FHIT has not been estimated in cancer cells. Here, we used HIV-TAT-derived peptide to transfer the purified FHIT protein into hepatocellular carcinoma cells and determined the biological effect of this fusion protein in inducing apoptosis. The affinity chromatography was used to purify TAT peptide fused human FHIT (TAT-FHIT) protein from BL21 <i>E. coli</i>. Immunofluorescence staining and Western blot were performed to identify the expression and internalization of TAT-FHIT in hepatocellular carcinoma cells compared with the purified FHIT protein. Our study showed that TAT-FHIT protein can translocate into cancer cells in one hour after incubation in 37&#x2103;. Furthermore, the results of MTT assay, Annexin-V staining and Western blot demonstrated that TAT-FHIT can robustly inhibit growth and induce apoptosis of hepatocellular cancer cells in vitro. In addition, mechanistic study showed that both exogenous and intrinsic apoptotic pathways were involved in TAT-FHIT-mediated apoptosis and this effect could be attenuated partially by a mitochondrial protector TAT-BH4, indicating that mitochondria plays a critical role in TAT-FHIT-mediated pro-apoptotic effect in cancer cells. Taken together, our study suggests that TAT-FHIT is a potential pro-apoptotic molecule in hepatocellular cancer cells and strengthen the hypothesis of its therapeutic application against hepatocellular carcinoma.]]></description>
	<dc:creator>G Yu, W Qin, J Li, W Hua, Y Meng, R Chen, B Yan, L Wang, X Zhang, L Jia, J Zhao, r zhang, A Yang</dc:creator>
	<dc:date>2011-06-16T12:37:20Z</dc:date>
	<dc:identifier>doi:10.1042/BSR20110033</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-06-16</prism:publicationDate>
</item>






</rdf:RDF>

